133 related articles for article (PubMed ID: 24152096)
1. Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?
Visani G; Isidori A
Expert Opin Pharmacother; 2014 Jan; 15(1):1-3. PubMed ID: 24152096
[TBL] [Abstract][Full Text] [Related]
2. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.
Nazha A; Kantarjian H; Cortes J; Quintás-Cardama A
Expert Opin Pharmacother; 2013 Oct; 14(14):1977-86. PubMed ID: 23875628
[TBL] [Abstract][Full Text] [Related]
3. A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Damlaj M; Lipton JH; Assouline SE
Expert Opin Drug Saf; 2016 Sep; 15(9):1279-86. PubMed ID: 27367461
[TBL] [Abstract][Full Text] [Related]
4. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
5. Omacetaxine mepesuccinate for the treatment of leukemia.
Kim TD; Frick M; le Coutre P
Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
[TBL] [Abstract][Full Text] [Related]
6. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
Chung C
Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine for the treatment of chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
[TBL] [Abstract][Full Text] [Related]
8. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
9. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
10. The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.
Nicolini FE; Chomel JC; Roy L; Legros L; Chabane K; Ducastelle S; Nicolas-Virelizier E; Michallet M; Tigaud I; Magaud JP; Turhan A; Guilhot F; Hayette S
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):394-9. PubMed ID: 21030353
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
12. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Quintás-Cardama A; Cortes J
IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
[TBL] [Abstract][Full Text] [Related]
13. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
15. Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
Klag T; Härtel N; Erben P; Schwaab J; Schnetzke U; Schenk T; Hochhaus A; La Rosée P
Leukemia; 2012 Jun; 26(6):1321-8. PubMed ID: 22289991
[TBL] [Abstract][Full Text] [Related]
16. Omacetaxine mepesuccinate in chronic myeloid leukemia.
Al Ustwani O; Griffiths EA; Wang ES; Wetzler M
Expert Opin Pharmacother; 2014 Nov; 15(16):2397-405. PubMed ID: 25301179
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Cortes J; Digumarti R; Parikh PM; Wetzler M; Lipton JH; Hochhaus A; Craig AR; Benichou AC; Nicolini FE; Kantarjian HM;
Am J Hematol; 2013 May; 88(5):350-4. PubMed ID: 23468307
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives.
Heiblig M; Sobh M; Nicolini FE
Leuk Res; 2014 Oct; 38(10):1145-53. PubMed ID: 24906663
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
20. Omacetaxine as an anticancer therapeutic: what is old is new again.
Wetzler M; Segal D
Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
